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Although sepsis is a systemic process, the pathophysiological cascade of events may vary from region to region.
Abdominal sepsis represents the host’s systemic inflammatory response to bacterial peritonitis.
It is associated with significant morbidity and mortality rates, and is the second most common cause of sepsis-related
mortality in the intensive care unit.
The review focuses on sepsis in the specific setting of severe peritonitis.Introduction
Abdominal sepsis is associated with significant morbidity
and mortality rates.
Results of prospective trials have often overestimated
the outcomes of patients with severe peritonitis [1]. Treat-
ment of patients who have complicated intra-abdominal
infections (IAIs) by adequate management, has generally
been described to produce satisfactory results; recent clin-
ical trials have demonstrated an overall mortality of 2% to
3% among patients with complicated IAIs [1,2].
However, results from published clinical trials may not
be representative of the true morbidity and mortality
rates of such infections. Patients who have perforated
appendicitis are usually over represented in clinical trials
[1]. Furthermore patients with intra-abdominal infection
enrolled in clinical trials have often an increased likeli-
hood of cure and survival. In fact trial eligibility criteria
often restrict the inclusion of patients with co-morbid
diseases that would increase the death rate of patients
with intra-abdominal infections.
After excluding patients with perforated appendicitis,
Merlino et al. [3] found that the cure rate among patients
who had intra-abdominal infections and were enrolled in
clinical trials, was much higher than that of patients who* Correspondence: massimosartelli@gmail.com
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unless otherwise stated.were not enrolled (79% versus 41%) and that the mortality
rate was much lower (10% versus 33%).
Epidemiological studies of patients with intra-abdominal
infections including severely ill subjects, have demon-
strated higher mortality rates [4].
In the CIAO study the overall mortality rate was 7.7%
(166/2152) [5]. Analyzing the subgroup of patients with
severe sepsis or septic shock at admission to hospital
the mortality rate reached 32.4% (89/274). In patients
with severe sepsis or septic shock in the immediate post-
operative period, the mortality rate was 42.3% (110/266).
Abdominal sepsis represents the host’s systemic in-
flammatory response to bacterial or yeast peritonitis.
In the event of peritonitis gram-negative, gram-positive,
as well as anaerobic bacteria, including common gut flora,
such as Escherichia coli, Klebsiella pneumoniae, Strepto-
coccus spp. and Bacteroides fragilis, enter the peritoneal
cavity. Sepsis from an abdominal origin is initiated by the
outer membrane component of gram-negative organisms
(e.g., lipopolysaccharide [LPS], lipid A, endotoxin) or
gram-positive organisms (e.g., lipoteichoic acid, peptido-
glycan), as well anaerobe toxins. This lead to the release of
proinflammatory cytokines such as tumor necrosis factor
α (TNF-α), and interleukins 1 and 6 (IL-1, IL-6). TNF-α
and interleukins lead to the production of toxic mediators,
including prostaglandins, leukotrienes, platelet-activating
factor, and phospholipase A2, that damage the endothelial
lining, leading to increased capillary leakage [6]. CytokinesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lial cells and neutrophils. Neutrophil-endothelial cell in-
teraction leads to further endothelial injury through the
release of neutrophil components. Activated neutrophils
release nitric oxide, a potent vasodilator that leads to septic
shock. Cytokines also disrupt natural modulators of coagu-
lation and inflammation, activated protein C (APC) and
antithrombin. As a result, multiple organ failure may occur.
Early detection and timely therapeutic intervention
can improve the prognosis and overall clinical outcome
of septic patients. However, early diagnosis of sepsis can
be difficult; determining which patients presenting with
signs of infection during an initial evaluation, do cur-
rently have, or will later develop a more serious illness is
not an easy or straightforward task.
Sepsis is a complex, multifactorial syndrome which
can evolve into conditions of varying severity. If left
untreated, it may lead to the functional impairment of
one or more vital organs or systems [7].
Severity of illness and the inherent mortality risk escal-
ate from sepsis, through severe sepsis and septic shock
up multi-organ failure.
Previous studies have demonstrated that mortality
rates increase dramatically in the event of severe sepsis
and septic shock [8]. Severe sepsis may be a reasonable
approximation of the “tipping point” between stable and
critical clinical conditions in the management of intra-
abdominal infections. Severe sepsis is defined as sepsis
associated with at least one acute organ dysfunction,
hypoperfusion, or hypotension.
It is well known that hypotension is associated with an
increased risk of sudden and unexpected death in patients
admitted to hospital with non traumatic diseases [9];
identifying patients with severe sepsis early and correcting
the underlying microvascular dysfunction may improve
patient outcomes. If not corrected, microvascular dys-
function can lead to global tissue hypoxia, direct tis-
sue damage, and ultimately, organ failure [10].
The Surviving Sepsis Campaign international guidelines
for management of severe sepsis and septic shock were
recently updated [11]. These guidelines are the corner-
stone for the management of severe sepsis and septic
shock, but they do not focus on the specific setting of
intra-abdominal infections.
Although sepsis is a systemic process, the patho-
physiological cascade may vary from organ to organ.
There are few data regarding systemic and local respon-
ses during peritonitis in humans and on their correlation
to patients outcomes [12-14].
Based on findings of high concentrations of cytokines in
the peritoneal compartment, some evidences suggested
that intra-abdominal sepsis may result in a cytokine-
mediated inflammatory response that is initially compart-
mentalized in the peritoneal cavity [15,16].Animal models have shown that peritonitis is associated
with a significant and prolonged peritoneal inflammatory
response which is adversely correlated with survival out-
come [17].
The levels of selected peritoneal cytokines have been
reported to be significantly different between animals
that survived as compared to those who died following a
septic challenge [18].
Plausibility of peritoneal compartmentalization of initial
inflammatory response during peritonitis was highlighted
by a recent prospective cohort study of patients with sec-
ondary generalized peritonitis [19]. It confirmed that IL-1,
TNFα, IL-6, IL-10 and IFNγ are present at high concen-
trations in the peritoneal fluid of patients with peritonitis.
The results of this study showed a large gradient between
peritoneal fluid and plasma concentrations of cytokines,
with no correlation between peritoneal and plasma levels,
suggesting that plasma levels may increase only after satu-
ration of tissues within the abdominal compartment.
The inflammatory response in patients with sepsis
depends on the causative pathogen and the host (genetic
characteristics and coexisting illnesses), with differential
responses at local, regional, and systemic levels [20].
The host inflammatory response probably changes
over time in parallel with the clinical course. Sepsis, in
the early stages of the inflammatory process, should be
considered as a local/peritoneal disease. In advanced
stages, severe sepsis and septic shock should be consid-
ered as a systemic disease, and patients who are extremely
unstable and exhibit high rates of mortality should be
managed more aggressively.
In certain patients peritonitis can quickly lead to an
excessive inflammatory response, and early and aggressive
mechanical peritoneal control is determinant for stopping
the septic process. In those patients inability to control or
interrupt the local inflammatory response is associated
with poor outcomes.
In patients with ongoing sepsis, several laparotomies
may be required. Under these circumstances, open abdo-
men allows the surgeon to perform subsequent laparoto-
mies more efficiently and prevent the onset of abdominal
compartment syndrome that may further worsen the
systemic disease.
The review focuses on management of patients with
severe sepsis or septic shock in the specific setting of
severe peritonitis.
Diagnosis
Reducing time to diagnosis of severe sepsis is thought to
be a critical component in reducing mortality from
sepsis-related multiple organ dysfunction [11]. Delineat-
ing the source of infection as accurately as possible prior
to surgery is the primary aim and the first step in man-
aging intra-abdominal infections. In severe abdominal
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lead to worse outcomes and early exploration is always
recommended when peritonitis is suspected even if the
source of infection is not recognized pre-operatively
with certainty.
The diagnosis of intra-abdominal sepsis is based primar-
ily on clinical assessment. Typically, the patient is admit-
ted to the emergency department with abdominal pain
and a systemic inflammatory response, including fever,
tachycardia, and tachypnoea. Abdominal rigidity suggests
the presence of peritonitis. However, clinical assessment
alone is not always reliable in critically ill patients due to a
variety of clinical constraints (e.g., impaired consciousness,
severe underlying disease, etc.). Hypotension, oliguria, and
acute altered mental status are waring signs of the pa-
tient’s transition from sepsis to severe sepsis.
Plain abdominal films are often the first imaging
obtained for patients presenting with peritonitis. Upright
films are useful for identifying free air under the dia-
phragm (most often on the right side), which can result
from perforated viscera. Free air may be present in most
cases of anterior gastric and duodenal perforation. How-
ever it is much less frequent with perforations of the small
bowel and colon and is unusual with appendiceal per-
foration. Abdominal plain films have low sensitivity and
specificity, and have, in most cases, been replaced by
abdominal computed tomography (CT). However, plain
films of the abdomen remain a reasonable initial study for
patients with suspected peritonitis who, on the basis of
history and physical examination, are likely candidates for
surgical exploration. In this case, abdominal plain films
may confirm evidence of perforation in short time.
Ultrasonography and computed tomography have be-
come essential diagnostic tools in abdominal sepsis. The
diagnostic approach to confirm the source of abdominal
infection in septic patients depends largely on the haemo-
dynamic stability of the patient [21].
Critically ill patients who are haemodynamically un-
stable or have developed severe acute respiratory distress
syndrome (ARDS) requiring high-level ventilatory sup-
port, are at significant risk during transport to the radi-
ology department In unstable patients who do not
undergo an immediate laparotomy and whose critical
condition prevents them from leaving ICU for further
imaging, ultrasound (US) is the best available imaging
modality [22]. It is portable, it can be performed at the
bed side, it is reproducible and can be easily repeated.
Major drawbacks are ileus and obesity, which may
significantly mask the US view. US is also strongly
operator-dependent. In suspected biliary sepsis US is
always the preferred initial diagnostic modality for
acute cholecystitis and emphysematous cholecystitis.
In stable patients, abdominal computerized tomog-
raphy (CT) is the imaging modality of choice, especiallywhen the diagnosis is uncertain. However, in patients
with severe sepsis, if the diagnosis of peritonitis is made
clinically or by previous radiological examinations (plain
films of the abdomen or US), additional CT scanning
may be unnecessary and would only delay much-needed
surgical intervention [22].
Another option in the diagnosis of critically ill patients
suffering from intra-abdominal sepsis is bedside laparos-
copy, as it can avoid patient transport to the radiological
department or operating room is very accurate, and
maintains ICU monitoring [23]. Laparoscopy provides a
“minimally invasive” definitive modality to diagnose
intra-abdominal sepsis. It may quickly provide the neces-
sary information to address further management. However,
the overall mortality of patients undergoing diagnostic
laparoscopy in the ICU is high, regardless of diagnostic
findings during this procedure. The use of diagnostic lapar-
oscopy should be limited to patients in whom a therapeutic
intervention is strongly suspected [24].
Antimicrobial therapy
A key component of the first-line management of the
septic patient is the administration of IV antimicrobial
therapy. Antimicrobial therapy plays a pivotal role in the
management of intra-abdominal infections, especially in
patients with severe sepsis who require immediate em-
piric antibiotic therapy.
An insufficient or otherwise inadequate antimicrobial
regimen is one of the variables more strongly associated
with unfavorable outcomes in critical ill patients [25].
Empiric antimicrobial therapy should be started as soon
as possible in patients with severe sepsis with or without
septic shock [26-28].
A prospective observational study by Riché et al. involv-
ing 180 patients with secondary generalized peritonitis,
reported significantly higher mortality rates in patients
presenting with septic shock (35%) compared to those
presenting without it (8%) [29].
The role of the infecting pathogen on the patients
response in secondary peritonitis has been poorly
investigated.
Some authors support the concept of a ‘generic septic
response’ in which an identical immune response is trig-
gered by any type of bacteria [30,31].
Contrastingly, others suggest that different types of
pathogens may elicit various inflammatory responses,
despite a common pathway of activation.
Riche et al. have found that polymicrobial cultures or
anaerobes in the peritoneal fluid were associated with
more frequent septic shock [29].
A recent prospective cohort study showed that
patients in whom anaerobes or Enterococcus species
[19] were isolated from peritoneal fluid cultures released
more TNFα in their plasma than those who were infected
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pathogens may elicit various inflammatory responses,
was already highlighted in animal models. In rats with
peritonitis, Montravers et al. showed that adjunction
of Enterococcus faecalis was associated with increased
mortality as well as higher levels of TNFα and IL-6
in peritoneal fluid [32,33].
Evidence regarding a specific role of some pathogens
on the pattern of the sepsis response is rather small, pre-
venting any definitive conclusion from these results.
However it is well known that patients with severe
sepsis or septic shock may benefit from aggressive anti-
microbial treatment in order to curb the spread of
the multiple organ dysfunction syndrome caused by
an ongoing peritoneal trigger.
For these patients, a de-escalated approach may be the
most appropriate strategy. Increasing rates of resistance
and a more comprehensive understanding of the sepsis
process have prompted many experts to advocate the
use of broad-spectrum antimicrobial regimens in the
initial stages of treatment for sepsis [34,35]. Subsequent
modification (de-escalation) of the initial regimen be-
comes possible later, when culture results are available
and clinical status can be better assessed, 48–72 hours
after initiation of empiric therapy.
When treating abdominal sepsis, clinicians must be
aware that drug pharmacokinetics may differ significantly
between patients due to the variable pathophysiology of
sepsis, and must also take into account the pathophysio-
logical and immunological status of the patient [36].
The “dilution effect”, also called the ‘third spacing’
phenomenon, must be considered when administering
hydrophilic agents such as β-lactams, aminoglycosides,Table 1 Recommended dosing regimens of the most frequen
function [21]
Renal function
Antibiotic Increased Normal
Piperacillin/
tazobatam
16/2 g q24 h CI or 3.375
q6 h EI over 4 hours
4/0.5 g q6 h
Imipenem 500 mg q4 h or 250 mg q3 h
over 3 hours CI
500 mg q6 h
Meropenem 1 g q6 h over 6 hours CI 500 mg q6 h
Ertapenem ND 1 g q24 h
Gentamycin 9 to 10 mg/kg q24 hb 7 mg/kg q24 h
Amikacin 20 mg/kg q24 h 15 mg/kg q24 h
Ciprofloxacin 600 mg q12 h or 400 mg q8 h 400 mg q12 h
Levofloxacin 500 mg q12 h 750 mg q24 h
Vancomycin 30 mg/kg q24 h CI 500 mg q6 h
Teicoplanin LD 12 mg/kg q12 h for 3 to
4 doses; MD 6 mg/kg q12 h
LD 12 mg/kg q12 h for 3 to
4 doses; MD 4 to 6 mg/kg q1
Tigecycline LD 100 mg; MD 50 mg q12 h LD 100 mg; MD 50 mg q12 hand glycopeptides, which selectively distribute to the
extracellular space. Low plasma antimicrobial levels can
contribute to lower than expected antimicrobial con-
centrations in peritoneal fluid with potentially reduced
antimicrobial delivery to the target tissues. In fact, the
target plasma concentration (Ct) that should be achieved
with the loading dose (LD) depends solely on the volume
of distribution (Vd) of the drug (LD = Ct × Vd). If the Vd
is enlarged the Ct will results in a lower than expected
level with the standard LD [36].
Higher than standard loading doses of β-lactams,
aminoglycosides, or glycopeptides should be adminis-
tered to ensure optimal drug exposure to the infec-
tion site in patients with severe sepsis or septic
shock [36].
Lastly it should be kept in mind that the loading dose
of lipophilic antibiotics (Macrolides, Fluoroquinolones,
Tetracyclines, Chloramphenicol, Rifampicin, Linezolid)
which are not influenced by the “diluition effect”, should
not be influenced by the severe sepsis or septic shock
status [36].
Once appropriate initial loading is achieved, it is
mandatory to reassess the antimicrobial regimen daily,
because the pathophysiological changes that may occur,
may significantly affect drug disposition in the critically
ill patients. Lower than standard dosages of renally excre-
ted drugs must be administered in the presence of
impaired renal function, while higher than standard dos-
ages of renally excreted drugs may be needed for optimal
exposure in patients with glomerular hyperfiltration [36].
In Table 1 recommended dosing regimens of the most
frequently used renally excreted antimicrobials accord-
ing to renal function are illustrated.tly used renally excreted antimicrobials according to renal
Moderately impaired Severely impaired
3/0.375 g q6 h 2/0.25 g q6 h
250 mg q6 h 250 mg q12 h
250 mg q6 h 250 mg q12 h
1 g q24 h 500 mg q24 h
7 mg/kg q36–48 h 7 mg/kg q48–96 h
15 mg/kg q36–48 hb 15 mg/kg q48–96 h
400 mg q12 h 400 mg q24 h
500 mg q24 h 500 mg q48 h
500 mg q12 h 500 mg q24–72 h
2 h
LD 12 mg/kg q12 h for 3 to
4 doses; MD 2 to 4 mg/kg q12 h
LD 12 mg/kg q12 h for 3 to
4 doses; MD 2 to 4 mg/kg q24 h
LD 100 mg; MD 50 mg q12 h LD 100 mg; MD 50 mg q12 h
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efficacy against a certain microorganism can involve the
specific drug concentration and/or the time when the
drug is introduced to the binding site [36].
Concentration-dependent antibiotics, such as amino-
glycosides and quinolones, are more effective at higher
concentrations. They therefore feature a concentration-
dependent post-antibiotic effect, and bactericidal action
continues for a period of time after the antibiotic level
falls below the minimum inhibitory concentration
(MIC) [36].
Concentration-dependent agents administered in high
dosage, short-course, once-a-day treatment regimens
may promote more rapid and efficient bactericidal action
and prevent the development of resistant strains.
There is good evidence for extended duration of amino-
glycoside dosing in critically ill patients. In terms of tox-
icity, aminoglycosides nephrotoxicity is caused by a direct
effect on the renal cortex and the uptake into the renal
cortex can be saturated. Thus a dosing strategy of exten-
ded duration reduces the renal cortex exposure to amino-
glycosides and reduces the risk of nephrotoxicity [37].
Time-dependent antibiotics, such as β-lactams and
glycopeptides, demonstrate optimal bactericidal activity
when drug concentrations are maintained above the
MIC. Unlike concentration-dependent agents, they have
a negligible post-antibiotic effect.
The efficacy of time-dependent antibacterial agents in
severely ill patients is based on the constant mainten-
ance of supra-inhibitory drug concentrations; as such,
clinicians should consider multiple doses per day [38].
In critically ill patients, continuous infusion of β-lactam
antibiotics may facilitate faster and more consistent thera-
peutic levels as compared to intermittent bolus dosing. Al-
though randomized clinical trials are needed to confirm
these findings, continuous infusion of β-lactam antibiotics
has proven to be a useful time-dependent approach for
treating critically ill patients [39].
The empirically designed antimicrobial regimen is
based on the underlying severity of infection, the patho-
gens presumed to be involved, and the risk factors indi-
cative of major resistance patterns.
Intra-abdominal infections in critically ill patients can
be treated with either single or multiple antimicrobial
regimens depending on the range requirements of anti-
microbial coverage [40].
Piperacillin/tazobactam is a beta-lactam/beta-lactamase
inhibitor combination with in vitro activity towards gram-
positive (including Enterococci), gram-negative and anaer-
obic organisms [41].
Piperacillin/tazobactam retains in vitro activity against
broad-spectrum beta-lactamase-producing, many exten-
ded-spectrum beta-lactamase-producing Enterobacteria-
ceae and many Pseudomonas isolates [42]. It is still agood antimicrobial agent in critically ill patients with
community-acquired intra-abdominal infections.
Carbapenems have a spectrum of antimicrobial activity
that includes Gram-positive (except resistant gram posi-
tive cocci) and Gram-negative aerobic and anaerobic
pathogens.
Group 2 carbapenems include imipenem/cilastatin,
meropenem and doripenem, sharing activity against non-
fermentative gram-negative bacilli and being particularly
suitable for severe intra-abdominal infections [43].
Doripenem is a new 1-ß-methyl carbapenem which,
similarly to imipenem and meropenem, has a broad-
spectrum activity against Gram-positive, Gram-negative,
and anaerobic bacteria [44]. Doripenem seems more
effective, in vitro, than meropenem and imipenem against
Pseudomonas aeruginosa [44].
In the last few years carbapenem overuse has been
associated with increasing rates of resistance among
enterobacteriacea [45], particularly Klebsiella pneumo-
nia. From an epidemiological point of view, it is neces-
sary to control the spread of carbapenemase producing
gram negative bacteria by optimization of carbepenems
use. The use of carbapenems in critically ill patients is
acceptable and well indicated. Tigecycline represents a
valid option for complicated intra-abdominal infections
due to its favorable in vitro activity against enterococci,
ESBL-producing strains of E. coli and Klebsiella and
anaerobic organisms. Tigecycline has showed also con-
siderable antimicrobial activity against Acinetobacter spp
[46,47]. It does not have in vitro activity towards Pseudo-
monas aeruginosa and Proteus mirabilis.
Given its in vitro activity against multidrug resistant
(MDR) bacteria, tigecycline represents an interesting
treatment option for intra-abdominal infections at risk
for MDR [48].
Recently, an analysis of clinical trials for both approved
and unapproved indications for tigecycline (including one
trial on complicated intra-abdominal infections), showed
an increased risk of death among patients receiving tige-
cycline. This observation led to a FDA recommendation
against the use of tigecycline in severe infections [49].
Because of its tissue penetration in peritoneal and soft
tissues [50], tigecycline is a very useful drug used in
peritoneal infections. In patients with severe sepsis or
septic shock of abdominal origin, in which the inflam-
matory process extends to the circulatory system,
tigecycline should always be associated with another
antimicrobial.
Although the epidemiological role of candida species
in intra-abdominal infections has not yet been conclu-
sively defined by the medical community, the clinical
role of candida is nevertheless significant given that
invasive candidiasis is generally associated with poor
clinical prognosis. However, the presence of Candida in
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taminant and may not require treatment.
Fluconazole has been widely used for the treatment of
candidiasis since its approval by the FDA in 1990.
The azoles act primarily by inhibiting the cytochrome
P450-dependent enzyme lanosterol 14-alpha-demethylase,
necessary for the conversion of lanosterol to ergosterol in
the cellular membrane of fungi [51].
Most C. albicans isolated from invasive candidiasis
infections, remain fully susceptible to fluconazole, which
has been the treatment of choice for these infections in
most settings including intra-abdominal infections [52].
However, epidemiological data demonstrate that the fre-
quency of Candida infections is rising, with an increase
in the proportion of infections caused by non-albicans
Candida species that are intrinsically resistant or vari-
ably susceptible to fluconazole [52].
Several randomized clinical trials have demonstrated
the efficacy of the echinocandins in the treatment of
candidaemia and invasive candidiasis [53].
The echinocandins: anidulafungin, caspofungin, and
micafungin have a broad and similar spectrum of in vitro
and in vivo activity against most Candida spp. [54].
Echinocandins have several potential advantages over
fluconazole for the treatment of invasive candidiasis. They
have a broader spectrum of activity (encompassing flucon-
azole-resistant C. glabrata and C. krusei) and potent fungi-
cidal activity against most Candida species [55].
In the specific setting of intra-abdominal infections,
echinocandins are generally recommended as a first line
empiric therapy for critical ill patients, while fluconazole
is typically recommended for less severe cases [21].
Haemodynamic support
One of the most likely explanations for the high morbidity
and mortality rates associated with severe sepsis is the
development of cardiovascular insufficiency, which can
lead to global tissue hypoxia.
In severe sepsis, the early haemodynamic profile is char-
acterized by hypovolaemia, vaso-regulatory dysfunction,
and myocardial depression. Increased capillary leakage
and venous capacitance ultimately result in decreased ven-
ous return to the heart. Additionally, cytokines released
during the patient’s immune response may trigger further
myocardial depression.
These haemodynamic alterations associated with the
early stages of sepsis are often accompanied by an increase
in systemic oxygen demand and impaired oxygen delivery,
thereby inducing global tissue hypoxia. Global tissue hyp-
oxia may overstimulate endothelial cell activity, which can
subsequently lead to the systemic inflammatory cascade
characteristic of sepsis [56,57].
Early treatment with aggressive haemodynamic sup-
port can limit the damage of sepsis-induced tissuehypoxia and prevent the over stimulation of endothe-
lial activity.
Rivers et al. [58] demonstrated that early goal-directed
therapy (EGDT), initiated in the emergency department,
reduces the in-hospital mortality rates of patients in sep-
tic shock.
It has been established that the general prognostic value
of a lactate of 4 mM/L on hospital admission is important;
multiple studies have confirmed the risk stratification of
this lactate level for illness severity and mortality in both
the pre-hospital and in-hospital setting [59-63]. Lactate
clearance has also been associated with decreased mortal-
ity in patients with severe sepsis and septic shock [64].
However, 20 to 50% of septic shock patients do not have
elevated lactate levels at presentation or during their clin-
ical course, yet still develop organ failure [65-67].
Fluid resuscitation
Fluid resuscitation should be initiated as early as pos-
sible in the course of treatment for severe sepsis regard-
less of a patient’s lactate level.
Fluid resuscitation is a major component of cardiovas-
cular support in early sepsis. Although the need for fluid
resuscitation in sepsis is well established, the goals and
components of this treatment are still a matter of debate
also in patients with peritonitis.
The absence of clear benefits following the administra-
tion of colloid solutions compared to crystalloid [68],
supports a high-grade recommendation for the use of
crystalloid solutions in the initial resuscitation of pa-
tients with severe sepsis and septic shock [11].
Intravascular volume is the first parameter to be assessed
during hemodynamic optimization.
In patients with generalized peritonitis, fluid resuscita-
tion should be kept under control to avoid fluids overload,
which may aggravate gut oedema and lead to increased
intra-abdominal pressure. Increasing intra-abdominal
pressure causes progressive hypoperfusion of splanchnic
circulation. Pathophysiological effects include gut oedema
leading to bacterial translocation and release of cytokines,
therefore aggravating the sepsis cascade [69].
Several studies have already shown that a positive fluid
balance in critical illness may be strongly associated with a
higher severity of organ dysfunction and with worse out-
comes [70].
Pathophysiological mechanisms associated with the in-
flammatory response lead to capillary leakage. Although
crystalloids are isotonic, a significant amount of the
volume given may migrate into the extra-vascular space
due to increased capillary permeability and changes in
oncotic pressure.
In patient with severe generalized peritonitis excessive
infusion of fluids may become a counterproductive
strategy.
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sion develops in abdominal sepsis may have other im-
portant clinical consequences in addition to its impact
on sepsis resuscitation endpoints. Current surviving
sepsis guidelines emphasize the importance of traditional
mean arterial pressure (MAP) >65 mm Hg, central ven-
ous pressure (CVP) of 8–12 mmHg in combination with
a central venous oxygen saturation (ScvO2) > 70% and
Urine output >0.5 mL/kg/hr [11]. However, in patients
with severe sepsis or septic shock of abdominal origin,
high intra-abdominal pressure may profoundly influence
commonly used septic shock resuscitation endpoints
such as CVP (falsely elevated) and urine output (mark-
edly decreased).
Repeated intravesical measurements of intra-abdominal
pressure should be frequently performed in patients with
severe sepsis or septic shock of abdominal origin, to iden-
tify patients at risk for intra-abdominal hypertension.
Monitoring the fluid status of critically ill patients at risk
for intra-abdominal hypertension is crucial. In recent
decades we have witnessed rapid advances in fluid moni-
toring techniques. Pulmonary artery catheters (PACs) have
been widely used for more than three decades, but their
usefulness in improving patient outcomes seems disap-
pointing. Trials have consistently shown that PACs do no
improve patient outcomes and may significantly increase
medical costs [71]. With the declining use of PACs,
there has been an increasing number of alternatives
for hemodynamic monitoring.
Echocardiography is a useful noninvasive tool which
can directly visualize the heart and assess cardiac func-
tion. Its use was long limited by the absence of accurate
indices to diagnose hypovolemia and predict the effect
of volume expansion. In the last years echocardiography
has been used to develop new parameters of fluid re-
sponsiveness, taking advantage of its ability to monitor
cardiac function. Echocardiography has been shown to
predict fluid responsiveness accurately and is now a
complete and noninvasive tool able to accurately deter-
mine hemodynamic status in circulatory failure [72,73].
It is strongly operator-dependent, and it does not allow
continuous monitoring.
The PiCCO system (Pulse index Contour Continuous
Cardiac Output, Pulsion Medical Systems, Germany) is
another interesting alternative. It incorporates a transpul-
monary thermodilution technique (TPTD) and continu-
ous pulse contour analysis. It is minimally invasive and
does not require intracardiac catheterization. It can give
beat-by-beat monitoring of cardiac output, and can
provide accurate information on volume status [74].
Vasopressor agents
Vasopressor agents should be administered early in
patients with severe sepsis or septic shock of abdominalorigin to restore organ perfusion. Their early use may
prevent excessive fluid resuscitation.
Vasopressor drugs maintain adequate blood pressure
and preserve perfusion pressure thus optimizing blood
flow in various organs. Norepinephrine is now the first-
line vasopressor agent used to correct hypotension in
the event of septic shock [11]. Norepinephrine is more
efficacious than dopamine and may be more effective for
reversing hypotension in patients with septic shock.
In 1993, Martin et al. showed in a prospective, double-
blind, randomized trial that norepinephrine was more
effective and reliable than dopamine to reverse the abnor-
malities of hyper dynamic septic shock [75]. The Surviving
Sepsis Campaign guidelines favour norepinephrine [11]
and there have been studies since the 2008 update to
bolster this preference. De Backer et al. investigated this
question in a meta-analysis, focusing only on those
patients with septic shock and again showed that
dopamine was associated with greater mortality than
norepinephrine [76].
It is well known that dopamine may cause more tachy-
cardia and may be more arrhythmogenic than norepin-
ephrine [77], and as an alternative vasopressor agent to
norepinephrine, it should be used only in patients with
low risk of tachyarrhythmias and absolute or relative
bradycardia.
Epinephrine is a potent α-adrenergic and β-adrenergic
agent that increases mean arterial pressure by increasing
both, cardiac index and peripheral vascular tone. There
are concerns regarding the use of epinephrine in septic
patients due to its potential to decrease regional blood
flow, particularly in the splanchnic circulation, and ele-
vations in serum lactate. However, no trials have shown
that epinephrine results in worse outcomes, so it may be
used as an alternative to norepinephrine [78,79].
Vasopressin is a peptide hormone synthesized in the
hypothalamus and subsequently transported to the pitu-
itary gland where it is stored. It is released in response
to decreased blood volume, decreased intravascular vol-
ume, and increased plasma osmolality. Vasopressin con-
stricts vascular smooth muscle by directly activating V1
receptors and simultaneously increasing the vasculature’s
responsiveness to catecholamines [80].
Vasopressin (up to 0.03 U/min) can be added to nor-
epinephrine with the intent of raising MAP to target or
decreasing the norepinephrine dose [11].
Inotropic agents
Dobutamine is frequently used to treat septic shock
patients as an inotropic agent increasing cardiac output,
stroke index, and oxygen delivery (Do2). However, the
tendency of dobutamine to increase Do2 to supra-
normal values in critically ill patients has raised serious
questions regarding its safety in the treatment of septic
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mend [11] that a dobutamine infusion should be adminis-
tered in the event of myocardial dysfunction as indicated
by elevated cardiac filling pressures and low cardiac out-
put or ongoing signs of hypoperfusion, despite achieving
adequate intravascular volume and adequate MAP.Acute kidney injury in surgical sepsis
In patients with surgical sepsis, particular attention
should always be paid to acute kidney injury (AKI). A
prospective observational institutional study recently
published, has shown that AKI frequently complicates
surgical sepsis, and serves as a powerful predictor of
hospital mortality in severe sepsis and septic shock. Dur-
ing the 36-month study period ending on December
2010, 246 patients treated for surgical sepsis were evalu-
ated in the study. AKI occurred in 67% of all patients,
and 59%, 60%, and 88% of patients had sepsis, surgical
sepsis, and septic shock, respectively.
Patients with AKI had fewer ventilator-free and inten-
sive care unit free days and a decreased likelihood of
discharge to home. Morbidity and mortality increased
with severity of AKI, and AKI of any severity was found
to be a strong predictor of hospital mortality (odds ratio,
10.59; 95% confidence interval, 1.28Y87.35; p = 0.03) in
surgical sepsis [81].Source control
Initial operation
The timing and adequacy of source control are of out-
most importance in the management of intra-abdominal
sepsis, as late and/or incomplete procedures may have
severely adverse consequences on outcome.
Source control encompasses all measures undertaken
to eliminate the source of infection, reduce the bacterial
inoculum and correct or control anatomic derangements
to restore normal physiologic function [82,83].
This generally involves drainage of abscesses or infected
fluid collections, debridement of necrotic or infected tis-
sues and definitive control of the source of contamination.
It is well known that inadequate source control at the
time of the initial operation has been associated with in-
creased mortality in patients with severe intra-abdominal
infections [84].
Early control of the septic source can be achieved
using both operative and non-operative techniques.
An operative intervention remains the most viable
therapeutic strategy for managing intra-abdominal sepsis
in critical ill patients.
The initial aim of the surgical treatment of peritonitis
is the elimination of bacterial contamination and inflam-
matory substances and prevention or reduction, if pos-
sible, of fibrin formation.Generally, the surgical source control employed de-
pends on the anatomical source of infection, the degree
of peritoneal inflammation and generalized septic response,
and the patient’s pre-morbid condition.
Surgical source control entails resection or suture of a
diseased or perforated viscus (e.g. diverticular perforation,
gastroduodenal perforation), removal of the infected organ
(e.g. appendix, gallbladder), debridement of necrotic
tissue, resection of ischemic bowel and repair/resection
of traumatic perforations with primary anastomosis or
exteriorization of the bowel.
Laparotomies are usually performed using a midline
incision.
The primary objectives of surgical intervention include
a) determining the cause of peritonitis, b) draining fluid
collections, c) controlling the origin of the abdominal
sepsis.
Special attention should be given to areas where
abscesses may form such as the pelvis, the para-colic
gutters, and the subphrenic spaces. These areas should
be carefully exposed and debrided, avoiding bleeding by
excessive peeling of the fibrin, and drained.
In case of suspected gastro-intestinal perforation, the
whole extent of the GI tract, starting from the gastroe-
sophgeal junction to the lower rectum should be thor-
oughly and carefully examined. If no perforation is found,
the gastrocolic omentum should always be opened to ex-
pose the lesser sac to allow visualization of the posterior
wall of stomach for any hidden perforation as well as care-
ful examination of the body and tail of pancreas.
Special attention should be paid while draining and
debriding the left subphrenic space since there is high
risk of splenic injury during surgical manipulation due
to fibrinous adhesions with the splenic capsule. Splenic
bleeding maybe difficult to control due to adhesions and
might warrant splenectomy which adds to the morbidity
and potential mortality in an already compromised
patient.
Intra-abdominal lavage is a matter of ongoing con-
troversy. Some authors have favoured peritoneal lavage
because it helps in removal as well as in dilution of peri-
toneal contamination by irrigation with great volumes of
saline [85]. However, its application with or without anti-
biotics in abdominal sepsis is largely unsubstantiated in
the literature [86].
In recent years, laparoscopy has been gaining wider
acceptance in the diagnosis and treatment of intra-
abdominal infections.
Laparoscopic approach in the treatment of peritonitis
is feasible and effective without any specific complica-
tions in experienced hands. Laparoscopy has the advan-
tage to allow, at the same time, an adequate diagnosis and
appropriate treatment with the less invasive abdominal
approach [87]. However, in unstable patients laparoscopy
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pressure due to pneumoperitoneum seems to have a nega-
tive effect in critical ill patients leading to acid–base bal-
ance disturbances, as well as changes in cardiovascular
and pulmonary physiology [88].
Relaparotomy strategy
In certain circumstances, infection not completely con-
trolled may trigger an excessive immune response and
sepsis may progressively evolve into severe sepsis, septic
shock, and organ failure [89].
Such patients would benefit from immediate and ag-
gressive surgical treatment with subsequent re-laparotomy
strategies, to curb the spread of organ dysfunctions caused
by ongoing sepsis.
Unfortunately, early assessment of the severity of peri-
tonitis is difficult in emergency surgical patients and
none of the existing and widely used ‘severity-of-disease’
scores, specifically developed for critically ill patients,
were clinically useful in the identification of patients
with ongoing infection needing a re-laparotomy [90].
Surgical strategies following an initial emergency lapar-
otomy include subsequent “re-laparotomy on demand”
(when required by the patient’s clinical condition) as
well as planned re-laparotomy in the 36-48-hour post-
operative period.
On-demand laparotomy should be performed only
when absolutely necessary and only for those patients
who would clearly benefit from additional surgery.
Several studies have evaluated clinical variables that may
be associated with the need for on-demand re-laparotomy
in the immediate post-operative period [91-97].
Van Ruler et al. [92] in 2008 reported the results of a
questionnaire asking surgeons to rank the importance of
21 clinical variables on their decision to re-operate in pa-
tients with secondary peritonitis. They found that diffuse
extent of the abdominal contamination, localization of the
infectious focus (upper gastrointestinal tract including
small bowel), and both, extremely low and high leukocyte
counts, independently predicted a re-laparotomy. These
variables had only moderate predictive accuracy. The re-
sults of the questionnaire demonstrated that there was no
consensus among surgeons about which variables are im-
portant in the decision-making process for re-laparotomy.
The final decision to perform a re-operation on a patient
in the on-demand setting is generally based on the patients
generalized septic response and on the lack of clinical
improvement.
Performing a case–control study, Koperna and Schulz
[91] retrospectively reviewed 523 consecutive patients
with secondary peritonitis. They focused their attention
on 105 patients, in whom standard surgical treatment of
secondary peritonitis failed and who had to undergo re-
laparotomy for persisting abdominal sepsis (study group).The authors showed that patients re-operated on after
48 hours had a significantly higher mortality rate than
those operated on earlier (76.5% versus 28%; p < .001).
Planned relaparotomies, on the other hand, are per-
formed every 36–48 hours for purposes of inspection,
drainage, and peritoneal lavage of the abdominal cavity.
The concept of a planned relaparotomy for severe
peritonitis has been debated for over thirty years. Re-
operations are performed every 48 hours for reassessing
the peritoneal inflammary process until the abdomen is
free of ongoing peritonitis; then the abdomen is closed.
The advantages of the planned re-laparotomy approach are
optimization of resource utilization and reduction of the
potential risk for gastrointestinal fistulas and delayed
hernias.
The results of a clinical trial published in 2007 investi-
gating the differences between on-demand and planned
re-laparotomy strategies in patients with severe periton-
itis found few advantages for the planned re-laparotomy
strategy; however, the study mentioned that this later group
exhibited a reduced need for additional re-laparotomies,
decreased patient dependency on subsequent health care
services, and decreased overall medical costs [98].
Open abdomen
An open abdomen (OA) procedure is the best way of
implementing re-laparotomies. The role of the OA in
the management of severe peritonitis has been a contro-
versial issue.
In 2007, a randomised study compared open and closed
abdomens for the “on demand re-laparotomy” group in
the treatment of severe peritonitis. The study was prema-
turely terminated following the treatment of 40 subjects
due to a significantly higher mortality rate in the open ab-
domen group compared to the temporarily closed abdo-
men group (55% vs. 30%). OA procedures were performed
using only non-absorbable polypropylene mesh [99].
Although guidelines suggest not to routinely utilize
the open abdomen approach for patients with severe
intra-peritoneal contamination undergoing emergency
laparotomy for intra-abdominal sepsis [100], OA has
now been accepted as a strategy in treating intra-
abdominal sepsis [101].
An OA approach in severe secondary peritonitis may be
required for three different reasons, often used in combin-
ation: inadequate source control, severely deranged physi-
ology (the operation is purposely abbreviated due to the
severe physiological derangement and suboptimal local
conditions for healing, and restoration of intestinal con-
tinuity is deferred to the second operation, i.e. the deferred
anastomosis approach) [102], and prevention of abdom-
inal compartment syndrome [103-105].
The rationale of the OA strategy in patients with
severe abdominal sepsis refers to the cytokine release
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Inability to control or interrupt the local inflammatory
response is associated with higher mortality rates in
these patients. The attenuation of the local inflammatory
response may be best achieved with mechanical control
by reducing the load of cytokines and other inflamma-
tory substances [106] and by preventing their produc-
tion, thus removing the source itself. Sometimes more
laparotomies are required to complete source control
and OA allows the surgeon to perform subsequent
planned laparotomies more efficiently.
An interesting non-comparative descriptive case series
[106] studied the inflammatory response in peritoneal
exudate and plasma of patients undergoing planned re-
laparotomy for severe secondary peritonitis. In septic pa-
tients undergoing re-laparotomy for severe peritonitis,
endotoxin, tumour necrosis factor alpha, interleukin-1
and interleukin-6 levels, were higher in the peritoneal
cavity then in plasma. When patients underwent re-
laparotomy, the level of those cytokines was significantly
decreased in survivors.
OA management has been described in patients with
intra-abdominal sepsis when a single laparotomy failed
to control local inflammatory response, or the risk of
organ dysfunction increased after effective drainage and
debridement [107-109].
In the event of massive fluid resuscitation, bowel
oedema and the forced closure of a non-compliant
abdominal wall may cause intra-abdominal hypertension
(IAH). Uncontrolled IAH exceeding 25 mm Hg may
cause abdominal compartment syndrome (ACS), which
is a potentially lethal complication characterized by
adverse effects on pulmonary, cardiovascular, renal,
splanchnic, and central nervous system physiology [109].
The combination of IAH and the physiological effects
of sepsis, result in high morbidity and mortality rates. At
present there are no definite criteria to guide the sur-
geon in deciding whether to use the OA strategy [110].
The OA strategy allows surgeons to extend the concept
of damage control surgery to abdominal severe sepsis.
The term damage control surgery (DCS) for trauma
patients was introduced in 1993. It was defined as initial
control of haemorrhage and contamination, allowing for
resuscitation to normal physiology in the intensive care
unit and subsequent definitive re-exploration [111,112].
The adaptation of damage control surgery for trauma
to other areas generally is useful in those patients who
are at risk to develop a similar loss of physiologic reserve
with intolerance to the shocked physiological state [113].
Similarly to the trauma patient with the lethal triad of
acidosis, hypothermia and coagulopathy, many patients
with severe sepsis or septic shock may present in a
similar fashion. For those patients, DCS can truly be life
saving. Patients progressing from sepsis through severesepsis with organ dysfunction into septic shock, can
present with vasodilation, hypotension, and myocardial
depression, combined with coagulopathy. These patients
are profoundly haemodynamically unstable and are
clearly not optimal candidates for complex operative in-
terventions [114].
Abdominal closure should be temporary, and the
patient is rapidly taken to the ICU for physiologic
optimization. This includes optimization of volume
resuscitation and mechanical ventilation, correction of
coagulopathy and hypothermia, and monitoring for
eventual ACS developement. Over the following 24 to
48 hours, when abnormal physiology is corrected the
patient can be safely taken back to the operating room
for re-operation.
An additional advantage of DCS in abdominal sepsis is
the possibility to delay the bowel anastomosis [115].
The surgical strategy for the management of patients
with compromised bowel in secondary peritonitis has
been usually the resection of the perforated viscus
followed by primary anastomosis or a diversion. In pa-
tients with severe secondary peritonitis and significant
hemodynamic instability and compromised tissue perfu-
sion, the use of primary anastomosis is limited because
of the high risk of suture/anastomotic failure, leakage,
and increased surgical mortality. In these patients, it is
advisable to control the source of peritoneal contamin-
ation and to perform an intestinal ostomy delaying
bowel anastomosis.
In a retrospective study from Colombia, 112 patients
with secondary peritonitis requiring bowel resection and
managed with staged laparotomy were analyzed [116].
Deferred primary anastomosis was used in 34 patients
where the bowel ends were closed at first operation and
definitive anastomoses were reconstructed at the subse-
quent operation following physiological stabilization in
the ICU and repeated peritoneal washes until the septic
source was controlled. In contrast, 78 patients under-
went small bowel or colonic diversion followed by simi-
lar ICU stabilization and peritoneal washes. In both
groups, the abdomens were left open at the initial oper-
ation and a Velcro system or vacuum pack was used for
temporary abdominal closure. The mean number of
laparotomies was four in both groups. There were more
patients with colon resections in the diversion group
(80% vs. 47%). There was no significant difference in
hospital mortality (12% for deferred anastomosis vs. 17%
for diversion), frequency of anastomotic leaks or fistulas
(9% vs. 5%), or ARDS (18% vs. 31%). The authors con-
cluded that in critically ill patients with severe secondary
peritonitis managed with staged laparotomies, deferred
primary anastomosis can be performed safely as long as
adequate control of the septic foci and restoration of
deranged physiology is achieved prior to reconstruction.
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with perforated diverticulitis (Hinchey III/IV), the patients
were managed either with sigmoid resection and primary
anastomosis, or limited sigmoid resection or suture, open
abdomen and primary anastomosis or colostomy at sec-
ond operation 24–48 hours later, or Hartmann procedure;
sigmoid resection and end colostomy [117]. All 6 patients
with primary anastomosis survived without complications,
but there was an obvious selection bias. Of the 6 patients
undergoing Hartmann’s procedure, one died of sepsis and
5 were discharged with stoma. In the interesting group of
15 patients with deferred anastomosis or stoma and open
abdomen, 9 patients had intestinal continuity restored
during the second look operation with one fatal anasto-
motic leakage.
In a prospective study of 51 patients with perforated
diverticulitis (Hinchey III/IV) were initially managed
with limited resection, lavage and TAC with vacuum-
assisted closure followed by second, reconstructive oper-
ation 24–48 hours later [118]. Bowel continuity was
restored in 38 patients, in 4 protected by a loop ileos-
tomy. Five anastomotic leaks (13%) were encountered
requiring loop ileostomy (2 patients) or Hartmann’s
procedure (3 patients). Postoperative abscesses were
seen in 4 patients, abdominal wall dehiscence in one and
re-laparotomy for drain-related small bowel perforation
in one. The overall mortality rate was 10% and 35/46
(76%) of the surviving patients left the hospital with re-
constructed colon continuity. Fascial closure was achieved
in all patients.
Following stabilization of the patient, the goal is the
early and definitive closure of the abdomen, in order to
reduce the complications associated with an open abdo-
men [119].
A review of the literature suggests a bimodal distribu-
tion of primary closure rates, with early closure dependent
on post operative intensive care management whilst
delayed closure is more affected by the choice of the tem-
porary abdominal closure technique [120].
Primary fascial closure can be achieved in many
cases within few days from the initial operation. It
would not be successful if early surgical source control
failed [121,122].
Sequential fascial closure could immediately be started
once abdominal sepsis is well controlled [123]. In these
cases, surgeons should perform a progressive closure,
where the abdomen is incrementally closed each time
the patient undergoes a reoperation.
Within 10 to 14 days the fascia retracts laterally and
becomes adherent to the overlying fat; this makes pri-
mary closure impossible. Therefore, it is important to
prevent the retraction of the myo-fascial unit.
Several materials can be used to achieve temporary
closure of the abdomen: gauze; mesh; impermeable self-adhesive membrane dressings, zippers and negative pres-
sure therapy (NPT) techniques.
The ideal temporary abdominal closure method should
be able to protect the abdominal contents, to prevent
evisceration, to allow removal of infected or toxic fluid
from the peritoneal cavity, to prevent the formation of
fistulas, to avoid damage to the fascia, to preserve the
abdominal wall domain, to make re-operation easy, safe
and facilitate definitive closure [110].
The surgical options for management of the OA are
now more diverse and sophisticated, but there is a lack
of prospective randomized controlled trials demonstrat-
ing the superiority of any particular method.
At present, negative pressure therapy (NPT) tech-
niques have become the most extensively used methods
for temporary abdominal wall closure. NPT actively
drains toxin or bacteria-rich intra peritoneal fluid and
has resulted in a high rate of fascial and abdominal wall
closure [110].
A systematic review conducted in 2012 [124] found
only 11 comparative studies, including 2 randomized
controlled trials (RCTs) and 9 cohort studies, examining
the efficacy and safety of negative pressure peritoneal
therapy versus alternate temporal abdominal closure
methods among critically ill or injured adults.
However, all studies were associated with at least a mod-
erate risk of bias and significant clinical heterogeneity, the
authors concluded that there was insufficient evidence to
support the preferential use of negative pressure periton-
eal therapy after damage control laparotomy.
Animal data suggest that OA techniques employing
constant negative pressure to the peritoneal cavity may
remove inflammatory ascites, reduce the systemic in-
flammatory response, and improve organ injury and po-
tentially outcomes [125].
This method is still associated with high morbidity
and high incidence of ventral hernia formation in surviv-
ing patients caused by difficulties in definitive closure of
the abdominal wall after prolonged application of NPT
but it could be a highly promising method in the man-
agement of patients with increased IAP and severe sepsis
due to severe peritonitis [126].
A systematic review published in 2009 [127] investigated
which temporary abdominal closure technique is associated
with the highest delayed primary fascial closure (FC) rate.
No comparative studies were identified. 51 articles
were included. The techniques described were vacuum-
assisted closure (VAC; 8 series), vacuum pack (15 series),
artificial burr (4 series), Mesh/sheet (16 series), zipper (7
series), silo (3 series), skin closure (2 series), dynamic re-
tention sutures (DRS), and loose packing (1 series each).
These results suggested that the artificial burr and the
VAC were associated with the highest FC rates and the
lowest mortality rates.
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combination of NPT with a temporary mesh sutured to
the fascial edges. The mesh is tightened every few days,
until the fascial defect is small enough so the mesh can
be removed and the fascia closed primarily.
In 2012, a retrospective analysis evaluating the use of
vacuum-assisted closure and mesh-mediated fascial trac-
tion (VACM) as temporary abdominal closure was pub-
lished [128]. The study compared 50 patients treated
with (VACM) and 54 using non-traction techniques
(control group). VACM resulted in a higher fascial closure
rate and lower planned hernia rate than methods that did
not provide fascial traction.
Occasionally, abdominal closure is only partially
achieved, resulting in late development of large, debilitating
hernias of the abdominal wall which will eventually require
complex surgical repair. In these cases, delayed repair or
use of biological meshes has been proposed [129].
Another option, if definitive fascial closure is not pos-
sible, is closure of the skin only and subsequent manage-
ment of the eventration by a deferred abdominal closure
with synthetic meshes after hospital discharge [127].Adjuntive measures
Recombinant human activated protein C (rhAPC), also
known as drotrecogin alfa, was included in the previous
Surviving Sepsis Campaign guidelines [130] based on the
PROWESS study group [131] and ENHANCE study
group [132] studies.
Based on the preliminary data of the PROWESS-
SHOCK study [133], showing a 28-day all-cause mortality
rate of 26.4% in patients treated with rhAPC compared
with 24.4% in those given placebo, the US Food and Drug
Administration (FDA) has withdrawn drotrecogin alfa
from the market [134] and now, rhAPC should not be
used in any patients with septic shock.Corticosteroids
The recommendations regarding the use of corticoste-
roids have changed over time and the clinical benefits of
corticosteroids in the treatment of severe sepsis and
septic shock remain controversial.
A systematic review of corticosteroids in the treatment
of severe sepsis and septic shock in adult patients pub-
lished in 2009 valued 17 randomized trials (2138 patients)
and 3 quasi-randomized trials (n = 246) of acceptable
methodological quality, and pooled the results in a subse-
quent meta-analysis [135]. The authors concluded that
corticosteroid therapy has been used in varied doses for
treating sepsis and related syndromes for more than
50 years, but its ability to reduce mortality rates has never
been conclusively proven. Since 1998, studies have con-
sistently used prolonged low-dose corticosteroid therapy,and follow-up analyses of this subgroup have found that
such regimens tend to reduce short-term mortality.
In 2011 Annane published an evidenced based guide
[136] regarding corticosteroids for severe sepsis. He con-
cluded that corticosteroids should be initiated only in
patients with sepsis who require 0.5 μg/kg per minute or
more of norepinephrine and should be continued for 5
to 7 days except in patients with poor haemodynamic
response after 2 days of corticosteroids and with a corti-
sol increment of more than 250 nmol/L after a standard
adrenocorticotropin hormone (ACTH) test.
The Surviving Sepsis Campaign guidelines [11] recom-
mend corticosteroids be used in patients with refractory
septic shock (poorly responsive to fluids and vasopressor
therapy) and do not recommend routine assessment for
relative adrenal insufficiency.
Nutritional support
The effect of nutritional support in critically ill patients
with sepsis has been debated in recent years. As for all
critically ill patients, nutritional support, preferably via
the enteral route, should be commenced in patients with
severe sepsis or septic shock once initial resuscitation
and adequate perfusion pressure is achieved [137].
Early enteral nutrition has theoretical advantages in
maintaining the integrity of the gut mucosa and on the
prevention of bacterial translocation.
Studies on different subpopulations of critically ill
patients, mostly surgical patients, are not consistent and
none was individually powered for mortality, with very
low mortality rates. Although no consistent effect on
mortality was observed, some early enteral feeding stud-
ies showed benefit on secondary outcomes such reduced
length of mechanical ventilation, and reduced ICU and
hospital stay [138-140].
Conclusions
The Surviving Sepsis Campaign international guidelines
for management of severe sepsis and septic shock were
recently updated. These guidelines are the cornerstone
for the management of severe sepsis and septic shock,
but they do not focus on the specific setting of intra-
abdominal infections.
Although sepsis is a systemic process, the pathophysio-
logical events differ for every organ and in the specific
setting of intra-abdominal infections the management of
sepsis may vary from that of sepsis of other etiologies.
Outcomes of severe intra-abdominal infections accom-
panied by severe sepsis are related to early diagnosis,
aggressive and early optimization of physiology, early
surgical management with source control and aggressive
critical care management. Reoperations are common
and may be useful in attenuating the inflammatory re-
sponse and optimizing the immune response.
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